PT 008 - Pediatrix Therapeutics
Latest Information Update: 29 Jan 2024
At a glance
- Originator Pediatrix Therapeutics
- Class Antihaemorrhagics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haemorrhage
Most Recent Events
- 17 Jan 2024 Preclinical trials in Haemorrhage (Prevention) in China (unspecified route) prior to January 2024 (Pediatrix Therapeutics pipeline, January 2024)